I Aced Every Cardiac Test. I Still Had an 80% Blockage.

I run 12-lead ECGs on patients every shift in the ER at Mayo Clinic. Mine came back textbook. So did my echo. So did my Holter. Meanwhile, the ACC, AHA, ESC, and NICE had all published guidelines saying the first test for a patient like me should be a CT coronary angiography — a CCTA, the scan that actually looks inside the arteries of your heart — not a stress test, not an echo, a CCTA. Since I was young, had no major risk factors, exercised, and outside of mildly high LDL all my other labs and tests were great, the cardiologist didn’t feel like the CT scan was needed. I had to fight for it. It found an 80% blockage. To say he was surprised would be an understatement — only eight years prior, this same test showed completely clear arteries. The evidence had already moved. The practice hadn’t. And I’m a clinician who knew to push back. Most patients don’t.

Last week I walked through the study the keto community relied on to claim that sky-high LDL doesn’t cause plaque, and how the follow-up data got retracted for uncorrectable methodological problems. That post was about the science I trusted. This one is about the tests I trusted.

Because here’s the thing that haunts me most about my own case: even after the diet question came into focus, every standard cardiac test told me I was fine. The science was wrong about LDL being benign. And the screening system was blind to the damage it caused.

The Clean Sweep

In the weeks before I was diagnosed with an 80% blockage of my right coronary artery, I ran through a cardiac workup at a major academic medical center. I didn’t just pass. I aced it.

My 12-lead ECG showed normal sinus rhythm. I run these all day in the ER. I know what a clean tracing looks like, and mine was textbook. My echocardiogram came back with normal wall motion, normal ejection fraction, no structural abnormalities. My Holter monitor tracked my heart rhythm for 48 hours and came back unremarkable. My Apple Watch and Oura Ring had never flagged a single abnormal reading. Resting heart rate in the low 50s. Labs to look for things like lipoprotein(a), a genetic risk factor for heart disease, were negative. So were other less-tested markers like homocysteine. My inflammation was fine — rock-bottom CRP. And as mentioned in other posts, no insulin resistance per hemoglobin A1c testing and my own experimentation with a continuous glucose monitor.

Every test said I was fine. Every metric pointed to a healthy heart in a healthy 44-year-old.

A few weeks later, I was pulling over on an interstate after reading a critical result on my phone: severe, flow-limiting occlusion of my right coronary artery. An 80% blockage. The interventional cardiologist told me only a few blood cells at a time were squeezing past it. I was one bad day away from a heart attack.

How does that happen? How does someone pass every standard cardiac test and still have severe coronary artery disease?

The answer isn’t complicated. It’s just uncomfortable: those tests weren’t designed to find what was killing me.

What These Tests Actually Do — And Don’t Do

A 12-lead ECG records the electrical activity of your heart over about 10 seconds. It’s a snapshot. It can detect arrhythmias, signs of an active heart attack, and sometimes evidence of a prior one. I use it dozens of times per shift. What it cannot do is see plaque inside your coronary arteries.

If the heart muscle is getting adequate blood flow at rest, the tracing looks normal. An artery can be 80 percent blocked and still deliver enough blood at rest to keep the electrical pattern clean.

Mahmoodzadeh et al. compared resting ECG findings against coronary angiography (the gold standard, where they thread a catheter in and look directly at the arteries) and found an overall sensitivity of just 51.5%.¹ In plain terms, that means the ECG missed nearly half of all real coronary disease cases. For the right coronary artery — the one that was 80% blocked in mine — the detection rate was just 25.8%.¹

The test most people think of as “checking your heart” catches a right coronary blockage about one in four times.

An echocardiogram uses ultrasound to look at your heart’s structure and function: chamber sizes, valve function, how the muscle is contracting. It’s the gold standard for structural heart disease. It is not a coronary artery test.

A resting echo looks at whether the heart muscle is moving properly. But if the coronary arteries are slowly narrowing and the muscle hasn’t yet been starved enough to sustain visible damage, the walls look fine. The ejection fraction (the percentage of blood the heart pumps out with each beat) looks fine. Everything looks fine. The echo can’t see the disease until the disease has already done serious damage.

My echo was pristine because my heart muscle was still being perfused, barely. The RCA was 80% blocked, but the remaining 20% was enough to keep the muscle alive and contracting normally at rest. The echo looked at the muscle and said “all good.” It never looked at the artery.

A Holter monitor records your heart rhythm continuously over 24 to 48 hours. It’s built to catch arrhythmias and rhythm abnormalities that might not show up on a 10-second ECG. It can also pick up signs of ischemia (when the heart muscle isn’t getting enough blood), but only if that ischemia happens to occur during the monitoring window.⁴ Mine was unremarkable because during those 48 hours, my blockage wasn’t causing enough oxygen deprivation to trigger a detectable change. The disease was there. It just wasn’t declaring itself.

Ischemia vs. Anatomy: The Blind Spot

This is the distinction that explains my case, and it’s the one most patients never hear.

All traditional cardiac testing (ECGs, echos, Holters, stress tests) is built around one question: Is the heart muscle getting enough blood right now? That’s called testing for ischemia. You stress the heart and look for signs that blood flow isn’t keeping up with demand.

But that’s not the same as asking: What do the arteries actually look like?

An 80% blockage can be compensated. The body can grow small detour vessels around the blockage, or the geometry of the narrowing might preserve enough flow. The stress test comes back normal. The plaque is still there.

The numbers on resting ECG above are bad enough. But even exercise stress testing (where you’re on a treadmill pushing your heart rate up) doesn’t fix the problem. A systematic review of 34 studies by Banerjee et al. found that exercise stress ECG catches coronary artery disease approximately 68% of the time.⁸ That means roughly one in three cases gets missed. For a disease that kills more people than any other condition on the planet, that miss rate should bother all of us.

And none of these tests can tell you anything about what kind of plaque you have — whether it’s calcified and stable, or soft and vulnerable to rupture. They detect the downstream consequence (ischemia) rather than the upstream cause (atherosclerosis). The entire traditional workup asks whether the heart is struggling right now. It never asks whether the arteries are diseased.

The Scale of What We’re Missing

Here’s where this stops being about my case and starts being about yours.

The PESA study imaged 4,184 asymptomatic adults aged 40 to 54 with no history of cardiovascular disease. These were bank employees in Madrid — middle-aged, apparently healthy people living normal lives.⁵

Sixty-three percent of them already had subclinical atherosclerosis — plaque building up silently in their arteries.

That’s not 63% of high-risk patients. That’s 63% of people who would have walked out of a standard cardiac workup with a clean bill of health. Among the men, it was 71%.⁵

Patel et al. examined 398,978 patients without known coronary artery disease who were referred for elective coronary angiography — the invasive test where they thread a catheter in to look directly.⁷ Only 37.6% had obstructive disease. The non-invasive functional tests that sent them there were wrong more often than they were right.

What Actually Looks at the Arteries

There are two tests that look directly at your coronary arteries for plaque.

Coronary artery calcium (CAC) scoring uses a non-contrast CT scan to quantify calcified — or hardened — plaque in the coronary arteries. It’s fast, relatively cheap, and low radiation. A score of zero is associated with very low short-term cardiovascular risk.⁹

But a zero doesn’t mean your arteries are clean. Osborne-Grinter et al. analyzed data from the SCOT-HEART trial and found that among patients with a calcium score of zero, 14% still had non-obstructive disease and 2% had obstructive disease on CT angiography.¹⁰ Sama et al. confirmed in a 2024 meta-analysis that approximately 10% of asymptomatic patients with zero calcium scores have non-calcified plaque.¹¹ The calcium score only sees hard plaque. It misses the soft plaque — the kind that can rupture. My own case makes the point: the majority of my RCA occlusion was not calcified. A calcium score alone might have missed it.

CT coronary angiography (CCTA) uses contrast dye and a CT scanner to create detailed images of the coronary arteries. It can see both calcified and non-calcified plaque, measure how much narrowing there is, and characterize what the plaque is made of. The ACCURACY trial demonstrated 95% sensitivity and a 99% negative predictive value (meaning if the CCTA says your arteries are clean, they’re almost certainly clean).¹²

The outcomes data is now definitive. The SCOT-HEART trial followed 4,146 patients for 10 years and found that patients who got CCTA had significantly fewer heart attacks — 4.3% versus 6.0%.¹⁵ The benefit didn’t come from more stents or surgeries. Revascularization rates were identical. The difference appears to have been that when doctors could actually see the plaque, they started preventive therapy — statins, escalated treatment. Seeing the disease changed the behavior. That’s a 10-year reduction in heart attacks driven entirely by better information.

The Guideline-Practice Gap

Here’s where I get angry. Not at my cardiologist. At the system.

In 2021, the ACC and AHA published updated chest pain guidelines recommending CCTA as the first-line diagnostic test for patients like me — symptomatic, middle-aged, no prior cardiac history, no known coronary artery disease.¹⁴ Class 1 recommendation, Level of evidence A. That’s the strongest possible endorsement in medicine. It means multiple randomized trials and meta-analyses agree, and the benefit clearly outweighs the risk. In 2024, the European Society of Cardiology reached the same conclusion.¹⁷ The UK figured this out even earlier — NICE recommended CCTA first-line in 2016 and reaffirmed it in 2024.¹³

So by the time I sat in a cardiology office, every major guideline society on the planet had already said: for a patient like me, the first test should be a CCTA. Not an EKG. Not an echo. Not a Holter. A CCTA.

I got an EKG, an echo, and a Holter. I had to fight for the CCTA. And I’m a Mayo Clinic ER nurse with a master’s in bioinformatics who reads primary literature because I enjoy it. Most patients don’t.

This is not about blaming individual doctors. My cardiologist is a skilled clinician. The stepwise approach he used was the standard of care for decades. The problem is that the evidence moved, the guidelines moved, and practice didn’t move with them. That happens in medicine more than any of us want to admit. And if it can happen at a major academic medical center, think about what’s happening in community cardiology practices and small rural towns without a cardiac CT scanner within 50 miles.

The barriers are real: reimbursement was so low that CMS significantly increased CCTA payment in 2025, there’s a widely reported shortage of physicians trained to read cardiac CT, and nuclear stress testing has massive installed infrastructure that institutions don’t abandon overnight. But none of those barriers change what the evidence says. And none of them should be invisible to the patient sitting in the exam room.

What This Means For You

If you’re in your 30s, 40s, or 50s. If you’ve been told your cholesterol is “borderline” but not worth treating. If you’ve had vague chest symptoms that were chalked up to anxiety. If you’ve passed a standard cardiac workup and been told your heart looks great — consider what that workup actually tested.

A clean 12-lead means your heart’s electrical system is working. A clean echo means your heart muscle is contracting properly. A clean Holter means your rhythm was stable. None of those tests looked inside your coronary arteries for plaque.

If you have risk factors — elevated LDL, family history, prior smoking — and want to know whether plaque is forming, talk to your doctor about a coronary artery calcium score as a starting point. If there’s clinical suspicion or risk factors that warrant it, ask about a CCTA. And if your doctor suggests a stress test first, it’s worth asking: “The current ACC/AHA guidelines recommend CCTA as first-line for symptomatic patients without known CAD. Can we discuss whether that applies to me?”

You shouldn’t have to know that. But right now, you might need to.

I had every advantage — clinical vocabulary, ER experience, a cardiologist at Mayo Clinic. And it still took every ounce of that advantage to get the test that found my disease. But getting the test was only half the fight. The other half was getting my cardiologist to order it in the first place.

That’s next week’s post.

---

This is not medical advice. It’s one clinician’s experience and a review of the published data. Talk to your doctor about what screening is appropriate for your individual risk profile.

---

For more evidence-based analysis of the claims shaping your health decisions, visit calibratedsignal.com. Hard science, delivered honestly. No sponsors. No cheerleading. Just signal.

References

1. Mahmoodzadeh S, Moazenzadeh M, Rashidinejad H, Sheikhvatan M. Diagnostic performance of electrocardiography in the assessment of significant coronary artery disease and its anatomical size in comparison with coronary angiography. J Res Med Sci. 2011;16(6):750-755. PMID: 22091303

2. [REMOVED — “ECG sensitivity 29%” claim unverifiable. See v2 changelog.]

3. [Reference removed — claim rewritten as established clinical knowledge; no specific citation needed.]

4. Stone PH. ST-segment analysis in ambulatory ECG (AECG or Holter) monitoring in patients with coronary artery disease: clinical significance and analytic techniques. Ann Noninvasive Electrocardiol. 2005;10(2):263-278. PMID: 15842439

5. Fernández-Friera L, Peñalvo JL, Fernández-Ortiz A, et al. Prevalence, vascular distribution, and multiterritorial extent of subclinical atherosclerosis in a middle-aged cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study. Circulation. 2015;131(24):2104-2113. PMID: 25882487

6. Berry JD, Liu K, Folsom AR, et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the CARDIA and MESA studies. Circulation. 2009;119(3):382-389. PMID: 19139385

7. Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective coronary angiography. N Engl J Med. 2010;362(10):886-895. PMID: 20220183

8. Banerjee A, Newman DR, Van den Bruel A, Heneghan C. Diagnostic accuracy of exercise stress testing for coronary artery disease: a systematic review and meta-analysis of prospective studies. Int J Clin Pract. 2012;66(5):477-492. PMID: 22512607

9. Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary calcium score and cardiovascular risk. J Am Coll Cardiol. 2018;72(4):434-447. PMID: 30025580

10. Osborne-Grinter M, Kwiecinski J, Doris M, et al. Association of coronary artery calcium score with qualitatively and quantitatively assessed adverse plaque on coronary CT angiography in the SCOT-HEART trial. Eur Heart J Cardiovasc Imaging. 2022;23(9):1210-1221. PMID: 34529050

11. Sama C, Abdelhaleem A, Velu D, et al. Non-calcified plaque in asymptomatic patients with zero coronary artery calcium score: a systematic review and meta-analysis. J Cardiovasc Comput Tomogr. 2024;18(1):43-49. PMID: 37821352

12. Budoff MJ, Dowe D, Jollis JG, et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY trial. J Am Coll Cardiol. 2008;52(21):1724-1732. PMID: 19007693

13. National Institute for Health and Care Excellence. Chest pain of recent onset: assessment and diagnosis. Clinical guideline CG95 (updated 2016); superseded by NG228 (2024). Available at: https://www.nice.org.uk/guidance/ng228.

14. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. Circulation. 2021. DOI: 10.1161/CIR.0000000000001029 PMID: 34709879

15. Williams MC, Wereski R, Tuck C, et al. (SCOT-HEART Investigators). Coronary CT Angiography and 10-Year Outcomes of Patients with Suspected Angina Due to Coronary Heart Disease. Lancet. 2025;405(10475):329-337. DOI: 10.1016/S0140-6736(24)02679-5 PMID: 39863372

16. Maurovich-Horvat P, Bosserdt M, Kofoed KF, et al. CT or Invasive Coronary Angiography in Stable Chest Pain (DISCHARGE). N Engl J Med. 2022;386(17):1591-1602. DOI: 10.1056/NEJMoa2200963 PMID: 35240010

17. 2024 ESC Guidelines for the Management of Chronic Coronary Syndromes. European Heart Journal. 2024;45(36):3415. PMID: 39210710

---

Nick Hanson, MS, RN, CEN
Mayo Clinic Board Certified Emergency Department RN
MS Bioinformatics & Computational Biology
Duke University APRN-FNP Candidate
Published Epigenetics and Oncology Researcher
Former Health & Wellness Industry CEO (15+ years)
Certified Personal Trainer (ISSA)